CORGARD pharmaceutical API fine chemical sources

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Molport	⤷ Get Started Free	MolPort-003-666-474	⤷ Get Started Free
Enamine	⤷ Get Started Free	EN300-50860	⤷ Get Started Free
AKos Consulting & Solutions	⤷ Get Started Free	AKOS015895037	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 28, 2025

Introduction

CORGARD (buprenorphine/naloxone) has become a cornerstone medication in opioid dependence treatment, offering an effective sublingual combination that mitigates misuse potential. As pharmaceutical companies and healthcare providers seek reliable supply chains, the sourcing of high-quality active pharmaceutical ingredients (APIs) for CORGARD is critical. This report assesses the current API supply landscape for buprenorphine and naloxone, focusing on manufacturers, geographic distribution, regulatory considerations, and supply chain stability.

Overview of CORGARD and API Components

CORGARD combines two APIs:

Buprenorphine: A semi-synthetic opioid with partial agonist activity at the mu-opioid receptor.
Naloxone: An opioid antagonist used to prevent misuse and treat overdoses.

The efficacy and safety of CORGARD hinge upon high-purity API sourcing, adherence to strict manufacturing standards, and consistent supply chains.

Global API Manufacturing Landscape

The API supply for CORGARD's active ingredients hinges on a mature and diverse global API manufacturing ecosystem. The primary regions involved include:

India
China
Europe
United States

Each region exhibits distinct strengths and regulatory environments, influencing sourcing decisions.

Leading API Manufacturers

Buprenorphine API Suppliers

Indivior/AbbVie (Originating from Indivior), United Kingdom
As the originator of buprenorphine products, Indivior supplies high-quality APIs predominantly for proprietary formulations. However, their API manufacturing facilities also produce bulk API for external use under strict GMP conditions.
Glenmark Pharmaceuticals (India)
A significant manufacturer of synthetic APIs, Glenmark offers high-purity buprenorphine intermediates and bulk APIs. Their facilities comply with global GMP standards, making them a favored supplier for generic formulations.
Mundipharma (Netherlands)
Mundipharma has strategic manufacturing partnerships focused on buprenorphine, with capable facilities producing APIs for both proprietary and generic products.
Mylan (USA/India)
A substantial supplier, Mylan produces buprenorphine APIs in their international manufacturing sites, offering cost-effective options with GMP compliance.
Hikma Pharmaceuticals (UK/Jordan)
Produces quality APIs for generic buprenorphine products, serving both domestic and international markets.

Naloxone API Suppliers

Glenmark Pharmaceuticals (India)
Also a key manufacturer of naloxone, Glenmark produces APIs that meet international standards, supporting rapid supply chains.
Hikma Pharmaceuticals (UK/Jordan)
Offers high-grade naloxone APIs with strong GMP compliance, favored for their reliability.
LTS Lohmann Therapie-Systeme AG (Germany)
Specializes in producing innovative opioid antagonists, including naloxone APIs, with a focus on clinical and generic applications.
Shanghai Sunflower Pharmaceutical (China)
A prominent producer of naloxone API, with export capabilities, though regulatory approval varies by region.
Hunan Jiedian Pharmaceutical (China)
Provides bulk naloxone API suited for generic formulations in various markets.

Regional Considerations and Regulatory Compliance

Regulatory standards are paramount. The manufacturers listed above are generally compliant with:

United States Pharmacopeia (USP)
European Pharmacopoeia (EP)
World Health Organization (WHO) GMP guidelines
Country-specific drug regulatory agencies (e.g., CDSCO in India, NMPA in China)

Importantly, global supply chain disruptions—amplified during the COVID-19 pandemic—highlight the necessity for diversified sourcing strategies. Companies sourcing APIs for CORGARD should perform rigorous due diligence to ensure GMP compliance and consistent quality.

Supply Chain Challenges and Risks

Consolidation among API producers poses risk; dependence on a limited number of suppliers may lead to shortages.
Regulatory disparities can delay approval or importation of APIs, especially from Chinese and Indian suppliers, where regional approvals vary.
Trade tensions and export restrictions may impact API availability and cost.
Quality assurance remains a top priority; substandard or counterfeit APIs threaten product safety and efficacy.

Sourcing Strategies for CORGARD API

To mitigate supply risks, pharmaceutical companies typically adopt multiple sourcing strategies:

Diversification: Engaging multiple approved API suppliers across regions.
Vertical integration: Some firms develop in-house API manufacturing capabilities.
Long-term supply agreements: securing contractual arrangements that ensure priority and price stability.
Regulatory compliance: prioritizing suppliers with a robust track record of GMP adherence to streamline approval processes in various markets.

Quality Assurance and Certification

Suppliers must hold valid GMP certificates (from respective regulatory agencies).
Certificates of analysis (CoA) should specify purity (>99%), residual solvents, and impurity profiles.
Ongoing audits and supplier qualification programs are standard practices in sourcing APIs for CORGARD.

Regional API Production Trends

India

India remains a dominant API manufacturing hub, providing cost-effective APIs for buprenorphine and naloxone, with many facilities attaining WHO-GMP and U.S. FDA approvals. The country’s robust pharmaceutical infrastructure supports large-scale API production, with increasing emphasis on regulatory compliance.

China

China’s API industry supplies a significant proportion of global APIs, including buprenorphine and naloxone. While cost advantages are notable, variability in regulatory oversight necessitates rigorous quality verification.

Europe and USA

European and American producers generally offer APIs with superior regulatory oversight, often preferred for high-quality standards, although at a premium price point. These are frequently used for marketing authorizations requiring robust quality documentation.

Regulatory Pathways for API Importation

Importing APIs for CORGARD involves adherence to:

FDA Drug Master Files (DMF)
European Drug Substances Master File (ESMF)
WHO Prequalification for supply to UN agencies

Manufacturers and importers must ensure documentation alignment with regional regulations and conduct comprehensive quality audits.

Conclusion

The supply ecosystem for CORGARD's APIs is mature and global, with key suppliers in India, China, Europe, and the United States. Ensuring a reliable supply chain necessitates diversification, stringent quality assurance, and alignment with regulatory standards. As the demand for CORGARD rises, particularly amid the opioid crisis, strategic sourcing will become increasingly vital to sustain manufacturing capacity and mitigate risks.

Key Takeaways

Diverse Global Suppliers: India and China dominate API production, with Europe and the US offering premium quality options.
Regulatory Compliance: Suppliers with current GMP certifications and robust quality controls are preferred.
Supply Security: Multi-sourcing strategies and long-term agreements reduce dependency on single sources.
Quality Assurance: Rigorous testing, certification, and ongoing audits are critical to regulatory approval and product safety.
Market Dynamics: Geopolitical factors, trade policies, and pandemic-related disruptions influence API availability and costs.

FAQs

1. Where can I source high-quality buprenorphine APIs for CORGARD?
Leading suppliers include Glenmark Pharmaceuticals (India), Mundipharma (Netherlands), and Mylan (USA/India), all GMP-compliant and capable of supplying APIs meeting international quality standards.

2. What regions are most reliable for naloxone API production?
India (Glenmark), the UK (Hikma), and Germany (LTS Lohmann) are recognized for consistent, high-quality naloxone API manufacturing aligned with global regulatory standards.

3. How do I ensure API quality and regulatory compliance?
Verify supplier GMP certifications, review Certificates of Analysis, conduct facility audits, and confirm adherence to regional pharmacopoeias like USP, EP, or WHO-GMP.

4. Are there risks associated with API sourcing from China and India?
Yes, including variability in regulatory standards, potential delays, and quality inconsistencies. Diversification and robust quality assurance mitigate these risks.

5. How has COVID-19 impacted API supply chains?
Disruption in manufacturing, export restrictions, and transportation delays have caused shortages. Diversifying sources and maintaining safety stock are recommended strategies.

Sources

[1] Indivior official website, API manufacturing details.
[2] Glenmark Pharmaceuticals, API product portfolio.
[3] European Medicines Agency (EMA) GMP certificates, API suppliers.
[4] WHO Prequalified Medicines database, API manufacturers.
[5] Market analysis reports on global API production and supply chain stability.

Bulk Pharmaceutical API Sources for CORGARD